Philippe Bedard
Philippe Bedard
Princess Margaret Cancer Centre
Verified email at
TitleCited byYear
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355, 2013
The genetic basis for cancer treatment decisions
JE Dancey, PL Bedard, N Onetto, TJ Hudson
Cell 148 (3), 409-420, 2012
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
HA Azim, S Michiels, PL Bedard, SK Singhal, C Criscitiello, M Ignatiadis, ...
Clinical cancer research 18 (5), 1341-1351, 2012
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy
F Cardoso, PL Bedard, EP Winer, O Pagani, E Senkus-Konefka, ...
Journal of the National Cancer Institute 101 (17), 1174-1181, 2009
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2013
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance
C Kollmannsberger, T Tandstad, PL Bedard, G Cohn-Cedermark, ...
J Clin Oncol 33 (1), 51-7, 2015
Luminal-B breast cancer and novel therapeutic targets
B Tran, PL Bedard
Breast Cancer Research 13 (6), 221, 2011
Cancer genomics: technology, discovery, and translation
B Tran, JE Dancey, S Kamel-Reid, JD McPherson, PL Bedard, AM Brown, ...
J Clin Oncol 30 (6), 647-660, 2012
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with …
PL Bedard, J Tabernero, F Janku, ZA Wainberg, L Paz-Ares, ...
Clinical Cancer Research 21 (4), 730-738, 2015
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
E de Azambuja, PL Bedard, T Suter, M Piccart-Gebhart
Targeted oncology 4 (2), 77-88, 2009
Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast …
HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ...
Cancer research 76 (4 Supplement), S5-07-S5-07, 2016
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
PL Bedard, A Di Leo, MJ Piccart-Gebhart
Nature Reviews Clinical Oncology 7 (1), 22, 2010
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen
Annals of Oncology 26 (9), 1824-1829, 2015
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 109, 2016
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial
B Tran, AMK Brown, PL Bedard, E Winquist, GD Goss, SJ Hotte, SA Welch, ...
International journal of cancer 132 (7), 1547-1555, 2013
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
M Knauer, F Cardoso, J Wesseling, PL Bedard, SC Linn, EJT Rutgers, ...
British journal of cancer 103 (12), 1788, 2010
Ocular toxicity of targeted therapies
DJ Renouf, JP Velazquez-Martin, R Simpson, LL Siu, PL Bedard
Journal of Clinical Oncology 30 (26), 3277-3286, 2012
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ...
Nature 563 (7732), 579, 2018
Stemming resistance to HER-2 targeted therapy
PL Bedard, F Cardoso, MJ Piccart-Gebhart
Journal of mammary gland biology and neoplasia 14 (1), 55-66, 2009
The system can't perform the operation now. Try again later.
Articles 1–20